Theralase reports 45% revenue growth and promising interim cancer trial results for Q1 2026.

Theralase Technologies reported a 45% revenue increase to CAD 132,634 in Q1 2026 and a reduced net loss of CAD 1.03 million compared to the previous year. The company highlighted positive interim results from its Phase II bladder cancer study, with 65.2% of patients achieving complete response and 40.4% maintaining it at 12 months. Theralase plans to submit regulatory applications in late 2026 and is pursuing partnerships for global commercialization. These developments mark significant progress toward offering a new treatment for BCG-unresponsive bladder cancer patients.